These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
497 related articles for article (PubMed ID: 17918481)
1. Finding a rational approach to ESA therapy--for payers and patients. Messana A Nephrol News Issues; 2007 Sep; 21(10):54, 56. PubMed ID: 17918481 [No Abstract] [Full Text] [Related]
2. ESA payment changes: chasing a moving target. Sargent JA Nephrol News Issues; 2008 Jan; 22(1):36-7. PubMed ID: 18271437 [No Abstract] [Full Text] [Related]
3. Erythropoietin claims monitoring policy: implications of the October 2006 update continuing. Messana T Nephrol Nurs J; 2006; 33(6):660-3; quiz 664-5. PubMed ID: 17219727 [TBL] [Abstract][Full Text] [Related]
4. Evolution of recombinant human erythropoietin usage in clinical practice in the United States. Is there an optimal way to use rHuEPO? Besarab A; McCrea JB ASAIO J; 1993; 39(1):11-8. PubMed ID: 8439674 [No Abstract] [Full Text] [Related]
8. The new label for erythropoiesis stimulating agents: the FDA'S sentence. Fishbane S; Jhaveri KD Semin Dial; 2012 May; 25(3):263-6. PubMed ID: 22515844 [TBL] [Abstract][Full Text] [Related]
9. The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now? Singh AK Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S5-13. PubMed ID: 19010260 [TBL] [Abstract][Full Text] [Related]
11. Economic considerations in a changing anemia environment. Pizzi LT Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S29-33. PubMed ID: 19010259 [TBL] [Abstract][Full Text] [Related]
12. Finding the magic formula for ESA use. Neumann ME Nephrol News Issues; 2010 May; 24(6):8. PubMed ID: 20509399 [No Abstract] [Full Text] [Related]
13. Erythropoietin, an update, and where to in the future? Sulková S EDTNA ERCA J; 1998; 24(3):30-2, 35. PubMed ID: 10392076 [TBL] [Abstract][Full Text] [Related]
14. Costs of managing anemia with erythropoiesis-stimulating agents during hemodialysis: a time and motion study. Schiller B; Doss S; DE Cock E; Del Aguila MA; Nissenson AR Hemodial Int; 2008 Oct; 12(4):441-9. PubMed ID: 19090867 [TBL] [Abstract][Full Text] [Related]
15. A lesson from the EPO mess: stop the cost shifting. Amerling R Nephrol News Issues; 2007 Jul; 21(8):52, 54-5, 68. PubMed ID: 17688232 [No Abstract] [Full Text] [Related]
16. The possible effects of CMS's 'non-decision' on a national coverage decision for ESA therapy. Cotter D; Thamer M; Zhang Y Nephrol News Issues; 2011 Aug; 25(9):15-6, 18. PubMed ID: 21905526 [No Abstract] [Full Text] [Related]
17. Impact of the change in CMS billing rules for erythropoietin on hemoglobin outcomes in dialysis patients. Ofsthun NJ; Lazarus JM Blood Purif; 2007; 25(1):31-5. PubMed ID: 17170534 [TBL] [Abstract][Full Text] [Related]
18. Report from the University Healthsystem Consortium. Int J Technol Assess Health Care; 1999; 15(2):437-8. PubMed ID: 10507201 [No Abstract] [Full Text] [Related]
19. Anemia management in dialysis: Why the FDA and CMS have it right (and how KDIGO got it wrong). Coyne DW Nephrol News Issues; 2013 Feb; 27(2):16, 18, 20. PubMed ID: 23469454 [No Abstract] [Full Text] [Related]